A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis (NCT07277660)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
Who can join: Review the eligibility criteria below.
Location: Atd002 52021 — Oceanside, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- Atd002 52021 — Oceanside, California
- Atd002 52008 — Santa Monica, California
- Atd002 52013 — Boca Raton, Florida
- Atd002 52007 — Miami, Florida
- Atd002 52003 — Miami, Florida
- Atd002 52015 — Savannah, Georgia
- Atd002 52017 — Chicago, Illinois
- Atd002 52018 — Wheaton, Illinois
- Atd002 52012 — New Albany, Indiana
- Atd002 52014 — Bowling Green, Kentucky
- Atd002 52001 — Troy, Michigan
- Atd002 52009 — Troy, Michigan
- Atd002 52010 — Omaha, Nebraska
- Atd002 52022 — New York, New York
- Atd002 52020 — The Bronx, New York
- Atd002 52019 — Philadelphia, Pennsylvania
- Atd002 52005 — Dallas, Texas
- Atd002 52016 — Frisco, Texas
- Atd002 52011 — Frisco, Texas
- Atd002 52004 — Sugar Land, Texas
- Atd002 41004 — Lovech,
- Atd002 41001 — Pleven,
- Atd002 41007 — Plovdiv,
- Atd002 41002 — Sevlievo,
- Atd002 41003 — Sofia,
📞 Contact the Study Coordinator
Phone: (844) 599-2273
Email: ucbcares@ucb.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.